Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bifocal & Atropine in Myopia (BAM) Study (BAM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03312257
Recruitment Status : Active, not recruiting
First Posted : October 17, 2017
Last Update Posted : November 27, 2018
Sponsor:
Information provided by (Responsible Party):
Jenny Huang, Ohio State University

Brief Summary:
This study will test whether the combined treatment of 0.01% atropine and soft bifocal contact lens wear produces slower myopia progression and axial elongation compared to soft bifocal contact lenses alone in children ages 7 to 11 years old.

Condition or disease Intervention/treatment Phase
Refractive Errors Combination Product: Multifocal D +2.50 add & 0.01% atropine Not Applicable

Detailed Description:

Both atropine and soft bifocal contact lenses have been shown to slow myopia progression, and both can cause changes in choroidal thickness. But the relationship between these mechanisms is unclear. The central hypothesis to be tested in the BAM Study is that atropine and soft bifocal contact lenses each exert their anti-progression actions through a common pathway that involves the choroid. If this is correct, then adding atropine treatment to soft bifocal contact lens wear will lead to a more effective slowing of myopia progression than prescribing soft bifocal contact lenses alone due to the additive effects in the common pathway.

The BAM Study is an ancillary study of an NIH sponsored multi-center, randomized clinical trial, the Bifocal Lenses In Nearsighted Kids (BLINK) Study (NIH: U10EY023208; NCT: NCT02255474). The BLINK Study compares myopia progression between subjects who wear single vision contact lenses and those wearing soft bifocal contact lenses. The BAM Study enrolls an additional 49 subjects that are age-matched with the participants who are wearing +2.50D add soft bifocal contact lenses in the BLINK Study. The subjects in the BAM Study wear +2.50D add soft bifocal contact lenses in combination with daily administration of one drop of 0.01% atropine in each eye for three years. The rates of myopia progression and axial elongation will be compared to the rates in participants who are receiving treatment with +2.50D add soft bifocal contact lenses alone in the BLINK Study.

Two specific aims will be addressed: Aim 1: To test whether the combined treatment of 0.01% atropine and soft bifocal contact lens wear produces slower myopia progression and axial elongation compared to soft bifocal contact lenses alone over 3 years. Aim 2: To test whether early changes in choroidal thickness can be used as predictors of long-term myopia progression / axial elongation. The results of this study will have significant implications for future studies to develop and test new therapeutic regimes that optimize the effect of myopia control through combined pharmacological and optical interventions. The outcomes will also aid in understanding the potential role of short-term changes of choroidal thickness in long- term regulation of myopia progression and ocular growth.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 49 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Myopia Control in Children With Low-dose Atropine and Soft Bifocal Contact Lenses
Actual Study Start Date : July 2016
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : June 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Multifocal D +2.50 add & 0.01% atropine
The Biofinity Multifocal "D" with a +2.50 add is a soft bifocal contact lens that has a strong reading power; the 0.01% atropine is a low-dose atropine.
Combination Product: Multifocal D +2.50 add & 0.01% atropine
Biofinity Multifocal D +2.50 add is a monthly disposable contact lens commercially available from CooperVision; 0.01% atropine is low-dose atropine compounded by local pharmacy.




Primary Outcome Measures :
  1. Refractive error progression [ Time Frame: 3 years ]
    Refractive error, as measured by cycloplegic autorefraction in both eyes, will be measured yearly to assess the difference in progression between the combination treatment (+2.50 D add soft bifocal lens and 0.01% atropine) group and the historical control group (+2.50 D add soft bifocal lens only) in the BLINK Study.


Secondary Outcome Measures :
  1. Axial length progression [ Time Frame: 3 years ]
    Axial length progression, as measured by Lenstar in both eyes, will be measured yearly to assess the difference in progression between the combination treatment (+2.50 D add soft bifocal lens and 0.01% atropine) group and the historical control group (+2.50 D add soft bifocal lens only) in the BLINK Study.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   7 Years to 11 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 7 to 11 years, inclusive, at baseline examination
  • -0.75 to -5.00 D, inclusive, spherical component, cycloplegic autorefraction
  • ≤1.00 DC, cycloplegic autorefraction
  • ≤ 2.00 D difference between the sphere components of the two eyes (anisometropia), cycloplegic autorefraction
  • 0.1 logMAR or better best-corrected visual acuity in each eye
  • 0.1 logMAR or better visual acuity OU distance and near with a +2.50 D add contact lens
  • +2.50 D add lens provides adequate fit with respect to movement and centration
  • Finish at least 71% of 0.01% atropine during the run-in period

Exclusion Criteria:

  • Eye disease or binocular vision problems (e.g., strabismus, amblyopia, oculomotor nerve palsies, corneal disease, etc.)
  • Previous intraocular or corneal surgery
  • Systemic disease that may affect vision, vision development, or contact lens wear (eg, diabetes, Down syndrome, etc.)
  • Previous gas permeable, soft bifocal, or orthokeratology contact lens wear or bifocal/PAL spectacle wear (longer than 1 month of wear)
  • Previous or current participation in myopia control studies
  • Chronic use of medications that may affect immunity, such as oral or ophthalmic corticosteroids for ocular or systemic diseases
  • Issues that may interfere with the ability to participate over the next 3 years

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03312257


Sponsors and Collaborators
Jenny Huang
Investigators
Layout table for investigator information
Principal Investigator: Juan Huang, PhD, OD The Ohio State Univeristy

Layout table for additonal information
Responsible Party: Jenny Huang, Research Assistant Professor, Ohio State University
ClinicalTrials.gov Identifier: NCT03312257     History of Changes
Other Study ID Numbers: K23EY025273 ( U.S. NIH Grant/Contract )
First Posted: October 17, 2017    Key Record Dates
Last Update Posted: November 27, 2018
Last Verified: November 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Refractive Errors
Eye Diseases
Atropine
Adjuvants, Anesthesia
Anti-Arrhythmia Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Mydriatics
Parasympatholytics
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action